The proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, ...
TCT 62: Long-Term Outcomes of Patients at Both High Ischemic and Bleeding Risk (Bi-Risk) on Clopidogrel-Based Dual Antiplatelet Therapy, Insights from the UF-GENOTYPE Registry. Receive the the latest ...
DALLAS, Nov 19 (Reuters) - Amgen Inc's experimental heart medicine from a closely watched new class of drugs called PCSK9 inhibitors lowered "bad" LDL cholesterol 52 percent after one year with no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results